Literature DB >> 21659766

The renin-angiotensin system.

Kar Neng Lai, Joseph C K Leung, Sydney C W Tang.   

Abstract

Diabetic nephropathy (DN) is a leading cause of end-stage renal disease in developed countries where type 2 diabetes mellitus has reached epidemic proportions. Although the exact pathogenesis of DN is not fully understood and is likely diverse in nature, there are convincing data that the renin-angiotensin system (RAS) is a major mediator of renal injury. Angiotensin II (Ang II), traditionally playing a central role as a mediator of glomerular hemodynamic adaptation and injury, is now recognized to exert proinflammatory action leading to upregulation of chemokines, adhesion molecules, and other fibrogenic growth factors that culminate in a decline of renal function. Hyperglycemia and mechanical stress deriving from glomerular hypertension are the key factors underlying pathogenesis of DN. The common signaling pathways stimulated by high glucose and mechanical insult may act synergistically, thereby accelerating the cell damage. Podocytes are subjected not only to the load of filtered glucose but also to diverse mechanical forces. Both high glucose and mechanical stress may impair the protein systems anchoring the podocyte foot processes in the glomerular basement membrane, therefore blunting resistance of these cells to mechanical forces in addition to the inflammatory insults. Loss of the podocytes is irreversible due to their inability to proliferate and to replenish damaged cells. Podocytes are injured early in the course of DN, which, most likely, underlies further glomerular and renal damage in diabetes. Under normal physiological conditions, podocytes play a specific role in the maintenance of intraglomerular RAS balance with enzymatic activities that predominantly lead to ANG1-7 and ANG1-9 formation, as well as Ang II degradation. ANG1-7 counteracts the proinflammatory actions of Ang II. These enzymatic activities are altered in a nonphysiological environment such as hyperglycemia that mimics diabetic kidney disease. An understanding of the local intraglomerular RAS will provide a novel approach for early stages of DN.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21659766     DOI: 10.1159/000325649

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  7 in total

1.  Calmodulin-dependent protein kinase II/cAMP response element-binding protein/Wnt/β-catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria.

Authors:  Lei Jiang; Lingling Xu; Yuxian Song; Jianzhong Li; Junhua Mao; Allan Zijian Zhao; Weichun He; Junwei Yang; Chunsun Dai
Journal:  J Biol Chem       Date:  2013-06-26       Impact factor: 5.157

Review 2.  Roles of the (pro)renin receptor in the kidney.

Authors:  Yoichi Oshima; Satoshi Morimoto; Atsuhiro Ichihara
Journal:  World J Nephrol       Date:  2014-11-06

3.  Effect of SWL on renal hemodynamics: could a change in renal artery contraction-relaxation responses be the cause?

Authors:  Erdal Yilmaz; Cagatay Mert; Zuhal Keskil; Devrim Tuglu; Ertan Batislam
Journal:  Urol Res       Date:  2012-09-04

4.  Angiotensin II receptor blocker attenuates intrarenal renin-angiotensin-system and podocyte injury in rats with myocardial infarction.

Authors:  Zhu-zhi Wen; Mu-yan Cai; Zun Mai; Dong-mei Jin; Yang-xin Chen; Hui Huang; Deng-feng Geng; Jing-feng Wang
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

5.  Progress in pathogenesis of proteinuria.

Authors:  Aihua Zhang; Songming Huang
Journal:  Int J Nephrol       Date:  2012-05-24

Review 6.  Recent advances in managing and understanding diabetic nephropathy.

Authors:  Sydney C W Tang; Gary C W Chan; Kar Neng Lai
Journal:  F1000Res       Date:  2016-05-31

7.  Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria by decreasing ANGPTL-4 expression.

Authors:  Lingyu Xue; Xiaoqing Feng; Chuanhai Wang; Xuebin Zhang; Wenqiang Sun; Kebo Yu
Journal:  BMC Nephrol       Date:  2017-10-04       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.